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Pancreatic cancer is one of the main causes of mortality and one of the most lethal malignant tumors worldwide [1]. 
Patient’s treatment includes surgery, radiation, chemotherapy or a combination of these approaches, with an 
average 20% five-year survival [1, 2]. In spite of recent advances in systemic chemotherapy, the median 
overall survival (OS) for pancreatic cancer patients remains poor (<1 year) and novel treatment strategies remain an 
unmet clinical need [3]. Chimeric antigen receptor (CAR) therapy employing autologous engineered T cells is capable 
of identifying tumor antigens through an HLA-independent mechan- ism [1]. T-cell therapy employs genetic 
engineering to redirect patient’s autologous T cells against malignant cells. The newest significant results in 
haematological cancer inspired investigation of CAR T-cell therapy in solid tumors such as pancreatic cancer [4]. CAR 
T-cell therapy was introduced after targeting CD19 for the treatment of lymphomas and leukemia in 1989 result- ing 
in significant growth in CART therapy and, as a direct consequence, in surface biomarker discovery [5]. Five clinical 
trials have been conducted until 2012, one  of them targeting Mesothelin antigen while the others targeting CD19 
antigen. The promising results from these preliminary studies with CAR T-cell and the fol- lowing research efforts led 
to the discovery of novel druggable biomarkers [6]. However, one major issue of this approach is the lack of specific 
targets for the treatment of solid tumors. Additionally, targets must be more specific and should not be expressed in 
healthy tissue [7]. Biomarker discovery is essential for the progress and success of CAR T therapy. Despite recent  
pro- gress, more research is still needed in the field of bio- marker identification, tumor cytotoxicity, cytokine 
release syndrome, persistence CAR T-cell in vivo, immunosuppressive tumor microenvironment [6]. Simultaneously 
with the development of immunother- apy in cancer, new markers are discovered and go through the validation 
process via clinical trials. Here we have summarized the most import studies, report- ing the preliminary preclinical 
data that may be useful for the next improvements for CAR T therapies. 
 




A comprehensive search of online literature databases including Medline, Embase, Cochrane  Library,  ISI Web of 
Science, and Google Scholar was carried out until March 2019 using the following medical subject headings (MeSH) 
words: “chimeric antigen T cell receptor”, “CAR T-cell therapy”, “CAR cell” and “pancreatic cancer”. The search was 
limited to animal preclinical studies and duplicate publications were removed. Language of publications was 
restricted to English. Only studies that reported outcomes of inter- est were included whereas letters, 
commentaries, and reviews were excluded. Two authors independently screened the studies based on titles and 
abstracts, and finally, if required, the full texts were reviewed. This systematic review has been carried out in 
agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [8]. 
Selection criteria Only studies that assessed CAR T-cell therapy in pan- creatic cancer animal models were included 
in our study. The researchers performed at least one com- parison between antigen targeted by CAR T-cell group 
and untreated group. Preclinical animal studies and peer-reviewed original articles were included in this systematic 
review. 
 
Study selection and data extraction 
Sahlolbei M. and Kheri B. independently screened the studies based on titles, abstracts, full texts and inclu- sion 
criteria using a checklist and reference lists of pertinent studies. The following extracted information and 
characteristics of all studies were  included:  author’s last name, year and country of the study population, animal 
group, animal protocol, animal sample size and gender, target, vector, CAR gener- ation, experimental and control 
group, model,  cell-  line, co-stimulatory domain, signaling domain, scFv  and animal protocol (Table 1). Two 
reviewers inde- pendently extracted data from all studies and the third author Dehghane M. resolved differences or 
discrep- ancies between investigators. 
 
Risk of bias assessment 
The methodological quality of included studies was assessed according to the SYstematic  Review  Center  for 
Laboratory Animal Experimentation (SYRCLE) for animal studies was adopted  from  the  Cochrane  Risk of Bias Tool 
[26]. The items (and  domains)  in  this  tool include critical Assessment of selection bias (sequence generation, 
baseline characteristics, and allocation concealment), performance bias (random housing and blinding), detection 
bias (random out- come assessment and blinded outcome assessment), attrition bias (completeness of outcome 
data), report- ing bias (selective reporting), and  other  biases.  For each eligible study, yes, no, and  unclear  
responses  were scored as low, high, and unclear risk of bias, respectively. All included studies were assessed inde- 
pendently by two authors for  all  10  SYRCLE  items and domains and verified by a Kiani J. Discrepancies  were 
resolved by consensus (Table 2). Statistical analysis All statistical analyses were performed using Stata ver- sion 13.0 
software (Stata Corp., College Station, TX, USA). Percentage and 95% CI were calculated by the percentage (ratio), 
standard deviation, and sample size in each study. Pooled cytotoxicity assay ratio (percent- age) and 95% confidence 
intervals were calculated by metaprop command using a random-effects model [27] with the inverse-variance 
weights  method  based on the transformed values and their variance [28]. We fitted the Freeman–Tuckey variant of 
the  arcsine  square root transformation of proportions to avoid variance instability when handling  proportions  
close to one [29]. Random-effects meta-analysis was used taking into account conceptual heterogeneity and due  to 
animal population and models,  CAR  generation,  cell lines, and designs across studies. Forest plot was produced to 
show the cytotoxicity assay ratio (per- centage) and corresponding 95% CI for visual inspec- tion across studies. 
Heterogeneity between studies was assessed using the I2 statistics  [30]  (I2¼0%  indicates  no observed 
heterogeneity and I2 2:50% indicates sub- stantial heterogeneity). The Cochran’s Q statistic was also used to analyze 
the statistical significance of the heterogeneity [31]. Sensitivity analysis  was performed to find out which study (if 
any) had the most impact   on the heterogeneity test and assess the robustness of summary findings. Visual 
inspection of funnel plots  was performed to assess the Publication bias [32]. Furthermore, Publication  bias  was  
formally  tested with Egger’s regression asymmetry tests for asym- metry of the funnel plots, where P < 0.10 was 
consid- ered evidence of bias. Begg’s adjusted rank correlation test and the trim-and-fill method for simulation were 





Using a systematic search of databases, 485 records  were identified. Of these, 292 studies including com- 
mentaries, editorials, study protocols, and irrelevant themes were removed. After screening by title  and abstract, 
56 studies reporting the therapeutic potential of CAR T-cell for pancreatic cancer were reviewed in depth. 16 
preclinical animal studies were eligible for inclusion in the systematic review and 11 studies  reported  the Cytokine 
Assay curve used for meta-analysis. Figure 1 shows a flow diagram relating to the selection of pub-  lished studies. 
 
Characteristics of studies 
Eight (8) subgroups of CAR T-cells were included: CAR T-Mesothelin (CAR T-meso), CAR T-Prostate stem cellantigen  
(CAR  T-PSCA),  CAR  T-Carcinoembryonic  anti-HER2),  NKG2  CAR  T  (family  of  C-type  lectin  receptors gen    (CAR 
T-CEA),    CAR  T-Mucin    (CAR  T-MUC),    CAR on  the  surface  of  NK  cells  CAR  T),  Cluster  of differenti- T-human  
epidermal  growth  factor  receptor  2  (CAR  T-ation   47  CART   (CD47-   CART)   and   CAR T-epidermalgrowth factor 
receptor (CAR T-EGFR). The animal  mod- els were induced by pancreatic cancer cell administered intraperitoneally, 
subcutaneously, or via tail vein injection. The majority of the animals were female, 4-6-week old, NOD mice or NSG 
mice. The doses of the interventions ranged from 105 to 107 CAR T -cells, which were injected intravenously 
approximately 15 days (when tumors became palpable) after induction of the pancreatic cancer  model. The main 
characteristics of the 16 studies included in the present systematic review are shown in Table 1. Studies have been 
conducted to investigate the quality of CAR T-Cell therapy performance in cell cultures and Laboratory Animals. It 
necessitates modi- fication of T cells evaluated in cell culture by Cytotoxicity assay, proliferation assay, lysis cell 
assay and so on. The next step is to transfuse the expanded  CAR T-cells injected into the mice at an appropriate 
dose. Finally, mice need to be  closely  monitored,  by Bio Luminescence, Tumor volume, Metastases num- ber, and 
Survival in the following few  days  (Data  shows in Supplemental Table1). 
 
Quality or risk of bias assessment 
All 16 articles in Table 1 were assessed methodologic- ally using the SYRCLE Risk of Bias tool. None of the studies was 
judged as having a low risk of bias across   all domains. The majority of  studies  reported  the  same group size, 
minimizing the risk of selection bias based on animal characteristics. Only a few studies explained the method of 
random sequence generation and animals for the experimental and control groups were allocated randomly. Most 
studies were scored as unclear risk. 
 
Main findings 
Based on our investigation on the cytotoxic effect of CAR T-cell, it has been shown that this treatment has the 
potential to kill pancreatic cancer cells. Our sub- group analysis observed that CAR  -PSCA  was  the  most efficient in 
pancreatic cancer animals treatment,  at the next rank of performance, dual CAR T-CEA/ MSLN, Meso, Her2/neu are 
located, respectively. Use   of dual CAR T-cell or its combination with  adeno-  virus or cytokine has been effective in 
increasing effi- cacy. CAR T immunotherapy significantly increased  the cytotoxicity assay in meta-analysis. There was 
no evidence for significant  heterogeneity  across  studies  [P ¼ 0.38 (Q statistics), I2 ¼ 7.14%]. Sensitivity ana- lysis, 
performed by successively removing a particular study at a time to assess the influence of every single study on 
pooled cytotoxicity assay, indicated that the meta-analysis model is robust. 
There was no evidence of publication bias regard-  ing the cytotoxicity assay ratio as a marker in treat- ment of 
pancreatic cancer (P ¼ 0.34, for Begg’s  adjusted rank correlation test and P ¼ 0.29 for Egger’s regression 





Pancreatic Cancer is the fourth cause of death in the United States of America and is predicted to be the second 
most lethal cancer in the world by  2030  [35, 36]. Simultaneously, initial results from immunothera- peutic studiesin 
solid tumor and hematologic malig- nancies have led to the development of multiple CAR    T therapies in pancreatic 
cancer [37]. Unlike conven- tional approaches used  to  manage  cancer  disease, CAR T-cell therapy is a patient-
specific, “living drug” and self-replicating drug approach in  the  elimination of resistant, metastatic or recurrent 
cancers [19]. As of the end of October 2019, there were about 350 CAR T-cell trials registered  onclinicaltrials.gov,  
but the  vast  majority  failed.  Optimizing  the  design  of CARs with the discovery of new, more specific antigen-
targets and the potential combination of CAR T-cell therapy with current approaches may help achieving effective 
treatment for pancreatic cancer [4]. Driving CAR T-cells against tumors via specific anti- gens in the setting of 
pancreatic  cancer will continue   to improve clinical trials. This is a fast evolving field  that has benefit from a few 
targets such as  Prostate  stem cell antigen (PSCA), antigens mucin1 (MUC1), mesothelin Carcinoma-Embryonic 
Antigen (CEA) and HER2 neu [3]. 
PSCA   is   a   glycosylphosphoinositol-anchored   cell surface antigen that is overexpressed in several major cancers 
including prostate, bladder and pancreatic cancer [38]. CAR specifically is capable  of  killing  PSCA expression in 
pancreatic cancer cell lines [39]. Besides,   the   preclinical   study   showed   that   CAR T -PSCA were able to reduce 
the size of pancreatic  tumors [13, 14]. Therefore, PSCA  has been proposed  as a biomarker of diagnosis and 
prognosis, as well as       a target of therapy for these cancers [40]. The low expression of PSCA in some normal tissue 
[39] might  be solved by creating dual-target CAR T-cells that can target both MUC-1 and  PSCA  simultaneously  and 
may reduce the risk of immune escape, but corres- pondingly  accept  the  risk  of  “on-target  off-tumour”toxicity 
[15, 41]. Since MUC1 is widely expressed in most epithelial-derived solid tumors, including pan- creatic and breast 
cancer, the MUC28z CAR  T-cells  will likely have broad applications, which may lead to successful eradication of  
above-mentioned  tumors [20]. CAR T-cell trafficking depends on the expression of receptors for chemokines 
secreted by the tumor.  CAR T-cells endogenously express chemokine recep- tors, but their cognate ligands are often 
not highly expressed by solid tumors. For improve trafficking to tumors, CAR T-cells can be engineered to express 
receptors for chemokines naturally secreted by the tumor [42]. A barrier in treating pancreatic cancer is  the release 
of inhibitory cytokines that can  suppress  the immune system and limit CAR T-cell performance and stability. 
Pancreatic tumors use immune evasion strategies such as the production of inhibitory cyto- kines, which limit CAR T-
cell function and persistence. Thus, to protect CAR T-cells from the immunosup- pressive cytokine IL-4, engendered 
inverted cytokine receptor in which theIL-4 receptor exodomain was joined to the IL-7 receptor endodomain (4/7 
ICR). The expression of this molecule in CAR T-PSCA can invert the inhibitory effects of tumor-derived IL-4 and pro- 
mote T cell proliferation, resulting in enhanced antitu- mor activity [12]. CAR T-cells designed to inhibit signals 
produced by the tumor environment for  example inhibitory signals such as TGFb, IL4 are expressed alongside CAR T-
PSCA (Smart T-cells). This approach is evaluated with the cytolyticactivity, viabil- ity, and expansion of CAR [17]. 
Mesothelin is a promising target for immune-based therapy, specifically for mesothelioma, pancreatic and ovarian 
cancers that have high levels of mesothelin expression. Many preclinical and clinical studies that target tumors 
expressing high mesothelin levels with antibodies, immunotoxins, antibody-drug conjugates and vaccines have 
shown the potential of mesothelin    as a target [43]. Pancreatic cancer is often reported to   be metastatic at early 
stages, which causes poor prog- nosis. One of the up-regulated antigens at the  final  stage is Mesothelin, normally 
observed only in fully transformed cells that have acquired metastatic fea- tures [38]. Findings showed that CAR T-
meso killed pancreatic cancer cells in vitro and inhibited subcuta- neous tumor growth in vivo. Also, CAR T-meso suc- 
cessfully repressed lung metastases originating from pancreatic cancer [10, 11]. 
To address these safety concerns while retaining potent cytotoxicity against cognate tumor cells, several innovative 
strategies have recently been described to regulate the selectivity and activity of CAR T-cells, including the suicide 
gene, inhibitory CAR, dual-antigen receptor, and an exogenous molecule used as a switch to control CAR T-cell 
activity [44]. 
Another novel approach of treating metastaic pan- creatic cancer is targeting the expression of antigen Her2/neu 
(ErbB2) human epidermal growth factor receptor 2 (HER2) which shows a 20-60% increased expression in pancreatic 
cancer [45]. In a study, CAR against Her2/neu was designed to stop the growth and metastasis of pancreatic 
xenografts  cancer  in  mice. The survival of mice was increased and some of them had no cancer-free after two 
months [22]. Low expression of HER2 antigen has been observed in lung and other tissues, which may be 
problematic in CAR T-cell therapy. For this purpose, Deepak Raj et al. have used switchable CAR T-cells to target  the  
antigen HER2. A major advantage of switchable CAR T-cells was their specific activation within the presence of a 
switch, which represent favorable option for neoplasm antigens with some expression on healthy tissue. These 
results corroborated it is efficacy against aggressive and disseminated pancreatic tumors [18, 21]. 
To enhance the specificity and controllable activity  of CAR T-cell therapy, engeenered T cells must distin- guish 
tumor tissues from normal tissues and prevent tumor escaping from immune surveillance [46]. Dual- receptor CAR 
(dCAR) can target CEA and mesothelin (MSLN) with a specific cytotoxic effect on cells that express both antigens 
[47]. Overall, this method can reduce “on-target, off-tumour” and “side effect” tox- icity against solid tumors. 
Pancreatic ductal adenocarcinoma is highly aggressive with immunosuppressive tumor microenvironment that limits 
T cell penetration and induces T cell hypofunction [16]. To overcome this barrier, a possible approach is to employ 
adenovirus with recombinant cytokines [9, 19]. Simultaneous use of CAR T- meso and oncolytic adeno- virus 
(expressing TNF-a and IL-2) enhanced the efficacy of CAR T- meso and showed significant tumor regres- sion in mice 
with pancreatic cancer [48]. 
CEA have highly expressed on the surface of pan- creatic adenocarcinoma cells. On the other hand physiologically 
expressed on healthy epithelium of the gastrointestinal tract and the lung so CEA is  not   tumor dedicated antigen 
[49]. Anti-CEA T-cells can eliminate CEA pancreatic carcinoma specifically and efficiently without inducing substantial 
autoimmunity when redirected by CAR. Unfortunately, increased serum level of CEA is found in cancer patients and 
might lead a major issue in the clinical outcome see-  ing soluble CEA can block T-cell recognition by bind- ing to the 
anti-CEA CAR [50]. 
Intratumoral hypoxia is a common feature of solid tumors. Recent advances in cancer biology  indicate  that hypoxia 
is not only a consequence  of  unre- strained tumor growth, but also plays an active role in promoting tumor 
progression, malignancy, and resist- ance to therapy [51]. Hypoxic conditions usually may alter the expression  of  
glycosyltransferases  [20]. MUC1 acts as a pivotal regulator of the metabolic sig- naling, facilitates metabolic 
alterations in hypoxic environments and promotes  tumor  cells  survivale [52]. CAR T targeting the Tn and STn 
antigens (com- mon tumor aberrant O-glycosylation sites) which is  able to specifically recognize multiple types of  
tumors  in vitro [53]. 
High-throughput screening showed several factors leading to the resistance of tumor cells to treatment. Among 
those, Indoleamine  2,  3-dioxygenase  1  (IDO1), an enzyme that metabolizes tryptophan to kynurenine acid caused 
a metabolic advantage to can- cer cells against T cells. IDO1 acts down-regulating T cell metabolism resulting in 
peripheral immune toler- ance and evasion of cancer from T cells [54]. Another gene, Galectin-9 (Gal-9) is  a  
tandem- repeat type galectin that has multiple biological func- tions such as cell adhesion and aggregation [55]. 
Cyclooxygenase (COX) 1/2 enzyme have a significant role in the synthesis of prostaglandin E2 (PGE2), a major player 
in angiogenesis, inflammation, and immunosuppression in cancer [56]. Results of tMUC1 CAR T-cells against 
treatment-refractory PDCA in combination with inhibitors against IDO1, COX1/2, and Gal-9 were promising. MUC1-
CAR T-cells have a synergistic effect with chemotherapy drugs [57]. 
A promising method is the use of  CARs not based  on a single-chain antibody variable fragment (for dir- ect antigen 
recognition) but relying on the activating  Fc-receptor CD16 [58]. Currently, CAR T- CD16- are evaluated in 
combination with monoclonal antibodies such as rituximab.  Preliminary  clinical  trials  have been tested combining 
the CD20-targeting antibody rituximab with a CD16-CAR T-cell product (NCT03189836). Cluster of Differentiation 
(CD) markers such as CD16, CD47  play an  important role  in pancreatic immunotherapy. The high-affinity of CD16 
158 V variant in combination  with  CART-  CD16 promotes anti-tumor activity. Furthermore, intra-tumoral injection 
of CD47-CAR T-cells signifi- cantly reduced BxPC3 (Human primary pancreatic adenocarcinoma). Humanized CD47-
CART-cells spe- cifically killed CD47-positive cancer cells [24, 59]. Nowadays, the main challenge is the inhibition of 
tumor-induced immunosuppressive mechanisms and remodeling the tumor microenvironment to be favor- able for 
delivering efficacious antitumor immunother- apeutics [60]. Additionally, the heterogeneity of tumor antigens in 
solid tumors usually leads to invalid immune surveillance and consequent relapsed tumor [61]. The paper aims to 
summarize CAR T therapy studies    to    increase    the    level    of    research-     ers’s knowledge. 
 
Limitations 
There are some limitations to  this  study.  Firstly,  all  the preclinical trials evaluating  CARs  have  small  group sizes, 
leading to  some  uncertainties  of  the result. Secondly, doses of CAR T-cells vary in different experiments, ranging 




Preclinical studies play a critical role  in  applying data to clinical trial practice and their outcome can be esti- mated 
more methodologically and objectively. Immunotherapy based on chimeric antigen have a positive effect on cancer 
treatment, along with trad- itional therapies. 
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